trastuzumab,capecitabine,tucatinib
Seagen
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'capecitabine', 't-dxd', 'tucatinib']
tucatinib + trastuzumab + capecitabine after t-dxd in her2+ mbs: orr= 32.5% pfs = 4.7 months os = 13.4 months poster 235 hall a #asco23 
Med Onc, Clinical Trials Development Leader @JulesBordet #BreastCancer #PrecisionMedicine. Views are mine https://t.co/F0nn6X9z9N…